A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
Date
1996Author
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Hanauske, A. R.
Gamucci, T.
Smyth, J. F.
Lehnert, M.
Velde, A. Te
Lan, J.
Verweij, J.
Source
Annals of OncologyVolume
7Issue
5Pages
529-531Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was given at two different dose schedules by a single bolus i.v. injection: arm A 12 mg/m2 weekly and arm B 22 mg/m2 every three weeks. All together 185 courses were administered (145 in arm A and 40 in arm B). The major toxicity was reversible proteinuria more frequently occurring in the three-weekly schedule (arm A 34.5% vs. arm B 62.5%). Creatinine elevation, fluid retention and pericardial or pleural effusion were also recorded in a limited number of patients. Other common toxicities more frequent in the three-weekly administration were asthenia (21% vs. 35% of cycles), nausea (15% vs. 27.5% of cycles) and Vomiting (5% vs. 17.5% of cycles). Toxicities were mainly of grade I and II. No responses have been observed. Five patients (26%) on arm A and eight (53%) on arm B experienced stable disease. These doses and schedules of EO9 do not yield activity in NSCLC.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Organization Studies: The Fourth Organization Studies Summer Workshop: “Embracing Complexity: Advancing Ecological Understanding in Organization Studies” 5—7 June 2008, Pissouri, Cyprus
Dooley, K. J.; Sandelands, L.; Tsoukas, Haridimos (2007)
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
A Longitudinal Study of Teacher Change: What Makes Professional Development Effective? Report of the Second Year of the Study
Boyle, Bill; Lamprianou, Iasonas; Boyle, Trudy (2005)